Inmune Bio Inc - INMB STOCK NEWS

INmune Bio (NASDAQ: INMB) has submitted an Investigational New Drug (IND) application to the FDA for its INKmune™ therapy aimed at treating metastatic castration-resistant prostate cancer (mCRPC). This trial, involving approximately 30 patients across multiple medical centers, focuses on assessing safety and determining the optimal dosage. The therapy seeks to convert patients' NK cells into cancer-fighting memory-like NK cells. Additionally, initial data from ongoing trials shows promising tumor-killing memory-like NK cells in patients without adverse side effects. The company emphasizes the potential of INKmune™ as a viable alternative to traditional chemotherapy.

INmune Bio, Inc. (NASDAQ: INMB) announced its financial results for the year ended December 31, 2022. The company reported a net loss of approximately $27.3 million, down from $30.3 million in 2021. R&D expenses were $17.1 million, a decrease from $20.5 million year-over-year. The firm highlighted advancements in its DN-TNF platform, merging trial efforts for Mild Cognitive Impairment and Alzheimer's Disease. It also received about $6.4 million in R&D rebates to enhance patient enrollment. The FDA review regarding a clinical hold on XPro™ AD trial is ongoing, with a Phase 2 trial anticipated to begin upon resolution. Cash reserves as of December 31, 2022, stood at $52.2 million.

INmune Bio, Inc. (NASDAQ: INMB) announced a conference call scheduled for March 2, 2023, at 4:30 PM ET. The call aims to discuss the results of its fourth quarter ending December 31, 2022, alongside a corporate update. Participants can join by dialing 1-877-407-0784 for domestic calls or 1-201-689-8560 internationally. A live webcast will also be available. Following the call, a transcript will be released approximately 24 hours later, and a replay can be accessed until March 9, 2023.

INmune Bio focuses on developing treatments that leverage the innate immune system against diseases, with ongoing clinical trials for its product platforms.

INmune Bio, Inc. (NASDAQ: INMB) announced it has received approximately $6.4 million in R&D refunds from Australia (~$3.7 million) and the UK (~$2.7 million). These funds will be reinvested into clinical programs, notably the ongoing Phase 2 Alzheimer’s Disease trial in Australia and Canada.

This non-dilutive funding will enhance recruitment and enrollment efforts, with plans to expand the trial internationally. CFO David Moss emphasized the importance of these rebates for continued collaboration with the FDA on the U.S. trial.

INmune Bio, Inc. (NASDAQ: INMB) has reported promising results from its collaboration with Professor Armando Villalta at UC Irvine, demonstrating that the Dominant-Negative TNF (DN-TNF) biologic significantly reduces muscle damage and promotes regeneration in a mouse model of Duchenne Muscular Dystrophy (DMD). Unlike current therapies that can cause adverse effects, DN-TNF selectively targets soluble TNF, presenting a novel approach to treating DMD and potentially other neuromuscular diseases. The company has formed a subsidiary to pursue DMD-specific development and is seeking partners for clinical advancement. Future publications and studies are planned to further evaluate this therapeutic.

INmune Bio has announced a grant from the Department of Defense for research into how traumatic brain injury (TBI) leads to Alzheimer’s disease. Collaborating with Virginia Commonwealth University and Barrow Neurological Institute, this project will study the effects of XPro1595 on TBI-induced AD pathology. Key researchers aim to uncover the role of soluble TNF in neuroinflammation and cognitive impairment post-TBI. The findings could pave the way for effective therapies for those with a high risk of AD.

INmune Bio (NASDAQ: INMB) will present data on INKmune™ therapy for patients with MDS or AML at the American Society for Hematology Conference in New Orleans, from December 10-13. The study, conducted at Southampton University, shows INKmune's safety in 4 patients and indicates sustained NK cell activation in 3. Notably, one patient exhibited long-lasting tumor-killing memory-like NK cells. The trial continues to enroll participants in the UK and EU, with plans to expand to the US for solid tumor indications. Key cytokines associated with immune responses were significantly altered post-treatment.

On December 6, 2022, INmune Bio presented findings at the 45th San Antonio Breast Cancer Symposium, highlighting the combination of INB03™ and trastuzumab-deruxtecan for treating HER2+ breast cancer. This combination could reverse resistance to HER2-targeted therapies, enhancing treatment efficacy and reducing toxicity. MUC4, a biomarker of resistance, is downregulated by INB03™, which improves anti-tumor immune responses. Key results showed significant tumor growth inhibition when INB03™ was included, with no added toxicity. This may lead to further immunotherapy opportunities for patients resistant to existing treatments.

INmune Bio will participate in the 15th CTAD Conference from November 29 to December 2 in San Francisco. The company is focused on developing therapies targeting Alzheimer's Disease (AD) through an innovative Phase 2 program using novel biomarkers and strategic trial design. Their XPro™ treatment aims to halt the progression of AD by utilizing unique patient criteria, cutting-edge neuroimaging technologies, and an effective cognitive endpoint called EMACC. INmune believes that their approach will surpass traditional anti-amyloid therapies.